Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Heritable defects in telomere and mitotic function selectively predispose to sarcomas.
Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour AP, Li S, Nguyen TL, Fatkin D, Graham RM, Giannoulatou E, Green MJ, Kaplan W, Ravishankar S, Copty J, Powell JE, Cuppen E, van Eijk K, Veldink J, Ahn JH, Kim JE, Randall RL, Tucker K, Judson I, Sarin R, Ludwig T, Genin E, Deleuze JF; French Exome Project Consortium; Haber M, Marshall G, Cairns MJ, Blay JY; International Sarcoma Kindred Study; Thomas DM, Tattersall M, Neuhaus S, Lewis C, Tucker K, Carey-Smith R, Wood D, Porceddu S, Dickinson I, Thorne H, James P, Ray-Coquard I, Blay JY, Cassier P, Le Cesne A, Duffaud F, Penel N, Isambert N, Kurtz JE, Puri A, Sarin R, Ahn JH, Kim JE, Ward I, Judson I, van der Graaf W, Seddon B, Chandrasekar C, Rickar R, Hennig I, Schiffman J, Randall RL, Silvestri A, Zaratzian A, Tayao M, Walwyn K, Niedermayr E, Mang D, Clark R, Thorpe T, MacDonald J, Riddell K, Mar J, Fennelly V, Wicht A, Zielony B, Gallig… See abstract for full author list ➔ Ballinger ML, et al. Among authors: barbour ap. Science. 2023 Jan 20;379(6629):253-260. doi: 10.1126/science.abj4784. Epub 2023 Jan 19. Science. 2023. PMID: 36656928
qmotif: determination of telomere content from whole-genome sequence data.
Holmes O, Nones K, Tang YH, Loffler KA, Lee M, Patch AM, Dagg RA, Lau LMS, Leonard C, Wood S, Xu Q, Pickett HA, Reddel RR, Barbour AP, Grimmond SM, Waddell N, Pearson JV. Holmes O, et al. Among authors: barbour ap. Bioinform Adv. 2022 Jan 31;2(1):vbac005. doi: 10.1093/bioadv/vbac005. eCollection 2022. Bioinform Adv. 2022. PMID: 36699384 Free PMC article.
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.
Chitty JL, Yam M, Perryman L, Parker AL, Skhinas JN, Setargew YFI, Mok ETY, Tran E, Grant RD, Latham SL, Pereira BA, Ritchie SC, Murphy KJ, Trpceski M, Findlay AD, Melenec P, Filipe EC, Nadalini A, Velayuthar S, Major G, Wyllie K, Papanicolaou M, Ratnaseelan S, Phillips PA, Sharbeen G, Youkhana J, Russo A, Blackwell A, Hastings JF, Lucas MC, Chambers CR, Reed DA, Stoehr J, Vennin C, Pidsley R, Zaratzian A, Da Silva AM, Tayao M, Charlton B, Herrmann D, Nobis M, Clark SJ, Biankin AV, Johns AL, Croucher DR, Nagrial A, Gill AJ, Grimmond SM; Australian Pancreatic Cancer Genome Initiative (APGI); Australian Pancreatic Cancer Matrix Atlas (APMA); Pajic M, Timpson P, Jarolimek W, Cox TR. Chitty JL, et al. Nat Cancer. 2023 Sep;4(9):1326-1344. doi: 10.1038/s43018-023-00614-y. Epub 2023 Aug 28. Nat Cancer. 2023. PMID: 37640930 Free PMC article.
The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer.
Barbour AP, Samra JS, Haghighi KS, Donoghoe MW, Burge M, Harris MT, Chua YJ, Mitchell J, O'Rourke N, Chan H, Gebski VJ, Gananadha S, Croagh DG, Kench JG, Goldstein D; Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators. Barbour AP, et al. Ann Surg Oncol. 2020 Jul;27(7):2506-2515. doi: 10.1245/s10434-020-08205-2. Epub 2020 Jan 29. Ann Surg Oncol. 2020. PMID: 31997125 Clinical Trial.
The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
Lonie JM, Brosda S, Bonazzi VF, Aoude LG, Patel K, Brown I, Sharma S, Lampe G, Addala V, Koufariotis LT, Wood S, Waddell N, Dolcetti R, Barbour AP. Lonie JM, et al. Among authors: barbour ap. Front Immunol. 2023 Oct 12;14:1220129. doi: 10.3389/fimmu.2023.1220129. eCollection 2023. Front Immunol. 2023. PMID: 37965317 Free PMC article.
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.
Bonazzi VF, Aoude LG, Brosda S, Bradford JJ, Lonie JM, Loffler KA, Gartside MG, Patel K, Mukhopadhyay P, Keane C, Gebski V, Kench JG, Goldstein D, Waddell N, Barbour AP; Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators. Bonazzi VF, et al. Among authors: barbour ap. Asia Pac J Clin Oncol. 2023 Jul 6. doi: 10.1111/ajco.13993. Online ahead of print. Asia Pac J Clin Oncol. 2023. PMID: 37415393
126 results